Effect of ivabradine on major adverse cardiovascular events and mortality in critically ill patients: a systematic review and meta-analyses of randomised controlled trials with trial sequential analyses

British Journal of Anaesthesia
Aileen ChenBernardo Bollen Pinto

Abstract

Ivabradine lowers heart rate (HR) without affecting contractility or vascular tone. It is licensed for HR control in chronic heart diseases. We performed a systematic review and meta-analyses to examine whether ivabradine could decrease major adverse cardiovascular events (MACE) and mortality in critically ill patients. We searched Medline, Embase, Cochrane Library, and Web of Science for RCTs. Trial quality was assessed using the Cochrane risk of bias tool. Random-effects meta-analyses were performed if at least three trials or 100 patients were available. Results are reported as weighted mean difference (WMD), odds ratio (OR), and 95% confidence intervals (CIs). Trial sequential analyses were performed to estimate the sample size needed to reach definitive conclusions of efficacy or futility. We included 13 RCTs (n=1497 patients). We found no evidence of an impact of ivabradine on MACE (three RCTs, 819 patients; OR=0.77; 95% CI, 0.53-1.11) or mortality (10 RCTs, 1356 patients; OR=1.07; 95% CI, 0.63-1.82), but sample sizes were not reached to allow definitive conclusions. Compared with placebo or standard care, ivabradine reduced HR (eight RCTs, 464 patients; WMD, -9.5 beats min-1; 95% CI, -13.3 to -5.8). Risk of bradycardia w...Continue Reading

Associated Clinical Trials

References

Jun 1, 1987·American Heart Journal·W B KannelL A Cupples
Feb 26, 2000·Journal of Internal Medicine·A ReunanenA Aromaa
Mar 16, 2006·JAMA : the Journal of the American Medical Association·Mustafa TomaPaul W Armstrong
Sep 16, 2006·BMJ : British Medical Journal·Joseph LauIngram Olkin
May 1, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Vincent C Tam, Sebastien J Hotte
Jul 16, 2008·Physiological Reviews·Dirk J Duncker, Robert J Bache
Jul 22, 2009·PLoS Medicine·David MoherUNKNOWN PRISMA Group
Feb 20, 2010·Circulation Research·Dario DiFrancesco
May 28, 2010·The European Journal of General Practice·Paul Van RoyenEva Hummers-Pradier
Nov 26, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Neeraj Parakh, Balram Bhargava
May 9, 2012·International Journal of Cardiology·Alberto Dominguez-RodriguezJuan Carlos Kaski
May 12, 2012·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Michael BöhmLuigi Tavazzi
Oct 11, 2013·JAMA : the Journal of the American Medical Association·Andrea MorelliMervyn Singer
Nov 14, 2013·European Heart Journal. Acute Cardiovascular Care·P G StegUNKNOWN VIVIFY (eValuation of the IntraVenous If inhibitor ivabradine after STsegment elevation mYocardial infarction) investigators
Sep 2, 2014·The New England Journal of Medicine·Kim FoxUNKNOWN SIGNIFY Investigators
Apr 18, 2015·Critical Care : the Official Journal of the Critical Care Forum·Silvia CoppolaDavide Chiumello
Sep 16, 2015·Intensive Care Medicine·A MebazaaJ Januzzi
Feb 14, 2016·Intensive Care Medicine·Davide Tommaso Andreis, Mervyn Singer
Oct 27, 2016·The American Journal of Cardiology·Jeffrey S BorerMichael Böhm
Dec 17, 2016·Current Opinion in Cardiology·Robert J H Miller, Jonathan G Howlett
Apr 30, 2017·BMC Cardiovascular Disorders·Hayelom Gebrekirstos MengeshaAbraha Hailu
May 26, 2017·Kardiologia polska·Kadir Uğur MertYüksel Çavuşoglu
Sep 22, 2017·Stroke; a Journal of Cerebral Circulation·Jessica S CranstonJeffrey L Saver
Dec 19, 2017·International Journal of Cardiology·Fabrizio OlivaEnrico Ammirati
Sep 3, 2018·International Journal of Clinical Pharmacy·Camila HartmannCristina Pellegrino Baena

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Related Feeds

Bradyarrhythmias

Bradyarrhythmias are slow heart rates. Symptoms may include syncope, dizziness, fatigure, shortness of breath, and chest pains. Find the latest research on bradyarrhythmias here.

Antianginal Drugs: Mechanisms of Action

Antianginal drugs, including nitrates, beta-blockers, and calcium channel blockers, are used in the treatment of angina pectoris. Here is the latest research on their use and their mechanism of action.